07:00 , May 9, 2011 |  BC Week In Review  |  Company News

Cadence, Incline Therapeutics deal

Cadence declined to exercise an option to acquire Incline for up to $135 million during the first of two option periods. The company said it made the decision because it wants to focus on the...
00:17 , May 6, 2011 |  BC Extra  |  Financial News

Cadence reports Ofirmev sales

Cadence Pharmaceuticals Inc. (NASDAQ:CADX) reported 1Q11 revenues of $400,000 for pain drug Ofirmev IV acetaminophen, which was launched in January. The Street was expecting revenue of $710,000. The company said the sales team focused primarily...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

J&J sales and marketing update

All batches of 25 µg/hr Duragesic fentanyl transdermal system CII patches manufactured by Johnson & Johnson 's Alza Corp. subsidiary were recalled because of potential damage to the patch that could result in direct exposure...
07:00 , Oct 3, 2005 |  BioCentury  |  Finance

Ebb & Flow

As a systemically delivered cancer drug, Genentech's Avastin clearly enjoys premium pricing. But the economics of the antibody, which costs $550 per 100 mg vial, could change dramatically in a non-systemic setting, where much less...
01:59 , Sep 29, 2005 |  BC Extra  |  Company News

FDA rejects Noven's generic fentanyl

NOVN dropped $2.50 (16%) to $13.06 on Wednesday after it and partner Endo (ENDP) announced that FDA will not approve an ANDA for the partners' transdermal fentanyl patch to treat chronic pain. FDA stopped its...
08:00 , Jan 31, 2005 |  BC Extra  |  Company News

Noven up on generic fentanyl news

NOVN was up $2.82 (18%) to $18.22 on 2.7 million shares on Monday following the company's announcement post-market last Friday that FDA denied citizen petitions that sought to delay FDA approval of generic fentanyl patches....
08:00 , Mar 1, 2004 |  BC Week In Review  |  Company News

Endo, Noven deal

ENDP received U.S. and Canadian rights to NOVN's transdermal fentanyl patch to manage chronic pain. NOVN redeived an $8 million payment and is eligible for an additional $5-$10 million. The companies hope to launch the...
08:00 , Dec 15, 2003 |  BC Week In Review  |  Clinical News

E-Trans transdermal fentanyl regulatory update

JNJ subsidiary Alza Corp. said it would not be able to submit an NDA in early 2004, as planned, for AP-48 fentanyl transdermal system to treat chronic pain. Alza said additional data are necessary to...
08:00 , Dec 15, 2003 |  BioCentury  |  Finance

Ebb & Flow

Market watchers may have found it strange that CV Therapeutics traded up following Tuesday's bearish FDA panel meeting on CVTX's Ranexa ranolazine to treat chronic angina. But the stock had fallen below cash on Monday,...
08:00 , Dec 9, 2003 |  BC Extra  |  Company News

Alza delays fentanyl NDA

Johnson & Johnson (JNJ) subsidiary Alza said it will not be able to file an NDA for AP-48 fentanyl transdermal system to treat pain in early 2004, as was expected. Alza said additional data are...